Loading...
Loading...
JNCE| Name | Value |
|---|---|
| Revenues | 82.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 82.0M |
| Operating Expense | 31.7M |
| Operating I/L | 50.3M |
| Other Income/Expense | 0.7M |
| Interest Income | 0.0M |
| Pretax | 51.1M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | 51.0M |
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company specializing in developing cancer treatments. Their primary focus is on vopratelimab, a monoclonal antibody in Phase II clinical trial, targeting the Inducible T cell CO-Stimulator found in solid tumors. Additionally, the company is developing JTX-8064, JTX-1484, and JTX-1811, which are antibodies designed to target specific cells and receptors within the tumor microenvironment. These innovative therapies demonstrate the company's commitment to advancing immunotherapy for cancer treatment.
